1. Introduction {#sec1-molecules-22-00267}
===============

Cancer is one of the most common lethal diseases, with approximately 14 million new cases of cancer diagnosed and 8 million cancer-related deaths in 2012. This disease affects all populations in all regions according to the World Health Organization \[[@B1-molecules-22-00267]\]. The five most common incident sites of cancers are the lung, breast, colorectum, prostate, and stomach, constituting half of incident sites worldwide \[[@B1-molecules-22-00267]\]. In recent years, natural products, including materials originating from plants, animals and their derivatives, have been extensively studied as anticancer agents considering their availability, low toxicity, and economic affordability. Over 60% of anticancer drugs are natural products that have shown potential anticancer activities \[[@B2-molecules-22-00267]\], such as anti-proliferation \[[@B3-molecules-22-00267]\], anti-angiogenesis \[[@B4-molecules-22-00267]\], reversal of multidrug resistance (MDR) \[[@B5-molecules-22-00267]\], and antimetastasis \[[@B6-molecules-22-00267]\] effects.

The genus *Aconitum* belongs to the family *Ranunculaceae*, which comprises about 400 species distributed in the temperate regions of the northern hemisphere, with half of them distributed in China \[[@B7-molecules-22-00267]\]. Since ancient times, about 40 of these species have been widely used to treat apoplexy hemiplegia \[[@B8-molecules-22-00267]\], asthma \[[@B9-molecules-22-00267]\], and rheumatoid arthritis \[[@B10-molecules-22-00267]\] in China, Japan, and other Asian countries; some examples are *A. carmichaeli* Debx., *A. kusnezoffii* Rchb., *A. sinomontanum* Nakai, and *A. leucostomum* Vorosch. \[[@B11-molecules-22-00267]\]. Modern pharmacological studies have demonstrated that medicinal *Aconitum* plants can exert anti-inflammatory, analgesic \[[@B12-molecules-22-00267],[@B13-molecules-22-00267]\], anti-arrhythmia \[[@B14-molecules-22-00267]\], antioxidant \[[@B15-molecules-22-00267]\], antibacterial \[[@B16-molecules-22-00267]\], and anticancer effects \[[@B7-molecules-22-00267],[@B17-molecules-22-00267]\]. In anticancer therapy, *Aconitum* plants have been proven effective for several types of cancer, such as lung, stomach, and liver cancers \[[@B18-molecules-22-00267],[@B19-molecules-22-00267],[@B20-molecules-22-00267]\].

*Aconitum* plants chemically comprise alkaloids, flavonoids, steroids, and glycosides, and the main efficacy components as well as the toxic components are diterpenoid alkaloids \[[@B21-molecules-22-00267],[@B22-molecules-22-00267],[@B23-molecules-22-00267]\], which are reportedly some of the most promising, naturally abundant compounds for treating cancer \[[@B24-molecules-22-00267]\]. Diterpenoid alkaloids have been studied since the 1940s, and based on structural differences such as the number of carbon atoms on the mother nucleus, diterpenoid alkaloids are generally divided into four categories: C~18~-, C~19~-, C~20~-, and bis-diterpenoid alkaloids \[[@B25-molecules-22-00267],[@B26-molecules-22-00267],[@B27-molecules-22-00267],[@B28-molecules-22-00267],[@B29-molecules-22-00267]\]. This review focuses on the progress of diterpenoid alkaloids with different structures derived from *Aconitum* plants and some of their derivatives (e.g., lappaconitine, aconitine, songorine, pseudokobusine, and 11-veratroylpseudokobusine) with potential anticancer activities. We also summarize some of their antitumor mechanisms. We hope this work can serve as a reference for further developing *Aconitum* diterpenoid alkaloids as anticancer agents.

2. Chemical Structure of Diterpenoid Alkaloids {#sec2-molecules-22-00267}
==============================================

Nearly a thousand natural diterpenoid alkaloids have been reported to date, and a large part of them originate from *Aconitum* plants \[[@B30-molecules-22-00267]\], and C~19~-diterpenoid alkaloids are the most reported among them \[[@B27-molecules-22-00267]\]. C~19~-diterpenoid alkaloids evolve from C~20~-diterpenoid alkaloids and degenerate into C~18~-diterpenoid alkaloids by losing the 18th carbon atom \[[@B25-molecules-22-00267],[@B31-molecules-22-00267]\].

Based on the presence of oxygen-containing functional groups at the C-7 position, C~18~-diterpenoid alkaloids, which constitute a small group within the diterpenoid alkaloids, are classified aslappaconine or ranaconine types \[[@B28-molecules-22-00267]\]. Concerning the carbon skeleton and substituents at specific positions, the C~19~-diterpenoid alkaloids may be initially divided into aconitine, lycoctonine, pyro, lactonepe, 7,17-seco, and rearranged types \[[@B27-molecules-22-00267]\]. Compared with C~18~- and C~19~-diterpenoid alkaloids, the skeletal types of the C~20~-diterpenoid alkaloids are extremely complex, which may be divided into four classes, including 19 types \[[@B29-molecules-22-00267]\]. The majority of C~20~-diterpenoid alkaloids have an exocyclic double bond structure and are generally divided into atisine, denudatine, hetidine, hetisine, napelline, and anopterine types nowadays \[[@B32-molecules-22-00267]\].

[Figure 1](#molecules-22-00267-f001){ref-type="fig"} and [Figure 2](#molecules-22-00267-f002){ref-type="fig"} show the chemical structures of C~18~-, C~19~-, bis-diterpenoid alkaloids and C~20~-diterpenoid alkaloids with anticancer activities derived from genus *Aconitum*, respectively.

3. Anticancer Activities of Diterpenoid Alkaloids {#sec3-molecules-22-00267}
=================================================

3.1. C~18~-Diterpenoid Alkaloids {#sec3dot1-molecules-22-00267}
--------------------------------

Lappaconitine (**1**), a typical C~18~-diterpenoid alkaloid extracted for the first time in China from *A. sinomontanum* Nakai, is commonly used as postoperative analgesia and relief for clinical cancer pain as a non-addictive analgesic \[[@B33-molecules-22-00267],[@B34-molecules-22-00267]\]. Lappaconitine exerts an analgesic effect by inhibiting the voltage-dependent sodium channels, increasing norepinephrine release in the synaptic cleft, and inhibiting the release of substance P \[[@B35-molecules-22-00267]\]. Lappaconitine reportedly inhibits the proliferation of the human non-small cell lung cancer cells A549 dose dependently \[[@B36-molecules-22-00267]\]. With increased lappaconitine concentration, the proportion of A549 cells increased gradually in G1 + G0 phase and decreased in S and G~2~+M phases, and the apoptosis rate increased with the down-regulated expression of Cyclin E1. Lappaconitine can also inhibit the expression of VEGF-A, and the combination of lappaconitine and oxaliplatin can arrest the cells in G1/G0 phase and inhibit the expression of Cyclin E1 \[[@B37-molecules-22-00267]\].

As the derivative of lappaconitine (**1**), lappaconite hydrobromide can reportedly exert an efficient antitumor effect in mice by the National Institutes of Health (NIH) mice. In particular, the inhibition rates ranged within 11.20%--53.08%for liver tumor growth and within 29.81%--53.96% for S180 tumor growth \[[@B38-molecules-22-00267]\].

3.2. C~19~-Diterpenoid Alkaloids {#sec3dot2-molecules-22-00267}
--------------------------------

Lycaconitine (**2**) is a C~19~-diterpenoid alkaloid isolated from the roots of *Aconitum pseudo-laeve var. erectum* through bioassay-guided fractionation and repeated column chromatography. Although lycaconitine (**2**) does not present cytotoxicity to KB cells, it has potent inhibitory effects on pgp-MDR upon testing on the multidrug resistant human fibrocarcinoma KB V20C (resistant to 20 nM vincristine) \[[@B39-molecules-22-00267]\].

In the 1980s, preliminary experimental studies on the antitumor effect of aconitine (**3**) were performed by multiple medical institutions. They demonstrated that 200 μg/mL aconitine inhibited the proliferation of gastric cancer cells by inhibiting its mitosis, and that the inhibitory rate of hepatocellular carcinoma in mice was 47.77%--57.38% \[[@B18-molecules-22-00267]\]. Aconitine also reportedly has anticancer activity to the mice inoculated with gastric cancer cells and S180 cells, as well as the ability to inhibit the spontaneous metastasis of Lewis lung cancer cells \[[@B40-molecules-22-00267]\]. Moreover, aconitine (150--400 μg/mL) can significantly inhibit the proliferation of Hepal-6 hepatoma cells in vitro, with the inhibitory rate of Hepal-6 cells in C75BL/6 male mice ranging within 26.12%--65.43% at concentrations of 0.15 and 0.375 mg/kg \[[@B41-molecules-22-00267]\].

MDR is a key factor that hinders cancer treatment. The anticancer effect of aconitine (**3**) has been evaluated in drug-resistant human oral squamous cell carcinoma (KBv200), which shows that aconitine has a small inhibitory effect on the growth of KBv200 (IC~50~ = 224.91 μg/mL). However, aconitine can increase the sensitivity of vincristine to kill cells, and the IC~50~ values of vincristine in KBv200 are 0.2715 and 0.9185 μg/mL when combined with 12.5 and 6.25 μg/mL aconitine, respectively \[[@B42-molecules-22-00267]\]. Thus, aconitine is considered to have no significant cytotoxic effect and can even reverse the MDR of cancer cells. Through immunohistochemistry and gene chip technology, follow-up studies has shown that aconitine can downregulate the expression of Protein Pgp and change the expression of Mdr1 gene by affecting apoptosis-related genes and the mitogen-activated protein kinase (MAPK) signal transduction system, thereby ultimately reversing the drug resistance \[[@B43-molecules-22-00267],[@B44-molecules-22-00267]\].

(1α,6α,8α,14α,16α)-20-Ethyl-8,14-dihydroxy-1,6,16-trimethoxy-4-(methoxymethyl)-aconitane (**4**) was isolated from the roots of *Aconitum taipaicum* Hand.--Mazz, and cytotoxicity assays indicate that compound **4** exhibits stronger growth inhibitory than adriamycin against leukaemia cells HL-60 and K-562 \[[@B45-molecules-22-00267]\]. In the same year, compound **4** has been found to inhibit the proliferation and invasion of HepG2 (liver hepatocellular carcinoma) cells and arrest cells in G0/G1 phase to promote cell apoptosis, the mechanism involves the upregulation of Bax and Caspase-3 expression and the downregulation of Bcl-2 (B-cell lymphoma-2) and CCND1 expression \[[@B46-molecules-22-00267]\].

Found in *A. carmichaeli* Debx., five compounds including oxonitine (**5**), deoxyaconitine (**6**), hypaconitine (**7**), mesaconitine (**8**), and crassicauline A (**9**) show obvious cytotoxic activities against various cancers, such as leucocythemia, breast cancer, and liver cancer. Compared with two other diterpenoid alkaloids without cytotoxic activities, compounds **5**--**7** and **9** have two ester groups in the structure, which may have an effect on the cytotoxicity of the compounds \[[@B47-molecules-22-00267]\]. 8-*O*-Azeloyl-14-benzoylaconine (**10**) is also a new C~19~-diterpenoid alkaloid with two ester groups in the structure found in the roots of *A. karacolicum* Rapcs. It shows good antiproliferative activities with an IC~50~ of about 10--20 µM against HCT-15 (colon cancer cell), A549 (lung cancer cell line), and MCF-7 (breast cancer cell line) cells \[[@B48-molecules-22-00267]\].

Cammaconine (**11**) was isolated from the ethanol extract of *Aconitum vaginatum* Pritz. and identified by spectroscopic analysis. It has greater inhibitory effect on AGS (gastric cancer cell), HepG2, and A549 cells compared with 5-Fluorouracil \[[@B49-molecules-22-00267]\]. Two C~19~-diterpenoid alkaloids, neoline (**12**) and 14-*O*-acetylneoline (**13**) were further isolated and identified from an enriched alkaloid fraction of *Aconitum flavum* Hand.--Mazz; they have been proven to possess growth-inhibition effects on human gastric carcinoma SGC-7901, hepatic carcinoma HepG2, and lung cancer A549 cells \[[@B50-molecules-22-00267]\].

3.3. C~20~-Diterpenoid Alkaloids {#sec3dot3-molecules-22-00267}
--------------------------------

Together with cammaconine (**11**), anatisine-type C~20~-diterpenoid alkaloid named atisinium chloride (**14**) was isolated from *A. vaginatum* Pritz. and found to inhibit the growth of various cancers \[[@B49-molecules-22-00267]\]. In addition, songorine (**15**), 12-epi-napelline (**16**), and 12-epi-dehydronapelline (**17**) derived from *Aconitum flavum* Hand.--Mazz. inhibited the growth of SGC-7901 (gastric carcinoma), HepG2, and A549 cells such as neoline (**12**) \[[@B50-molecules-22-00267]\].

In 2007, 13 natural diterpenoid alkaloids were isolated and purified from *Aconitum yesoense* var. *macroyesoense* and *Aconitum japonicum* and 22 derivatives were subsequently prepared from the parent alkaloids. The veatchine-type C~20~-diterpenoid alkaloid named 12-acetylluciculine (**18**) and the six derivatives designed from pseudokobusine (**19**), including 6,11-dibenzoylpseudokobusine (**20**), 11-veratroylpseudokobusine (**21**), 11-cinnamoylpseudokobusine (**22**), 11-(*m*-trifluoromethylbenzoyl)pseudokobusine (**23**), 11-anisoylpseudokobusine (**24**), and 11-*p*-nitrobenzoylpseudokobusine (**25**) are proven to inhibit the growth of human malignant A172 cells \[[@B51-molecules-22-00267]\]. The hydroxyl groups at C-6 and C-15 of pseudokobusine are considered to be essential to the inhibitory effect, and the esterification of the hydroxyl group at C-11 may enhance such activity. In 2009, Koji Wada detected the anticancer activities of the same above mentioned diterpenoid alkaloids with four different cancer cells. They demonstrated that all six derivatives (**20**--**25**) have strong inhibitory activity against A172, A549, HeLa (cervical cancer cell line), and Raji (lymphoma cell line) cells (except compound **21** to HeLa cells) \[[@B52-molecules-22-00267]\]. Compounds **23** and **24**, which show significant suppressive effects against Raji cells, have the same structure except for the group in the C-11 position. Compound **23** inhibits the phosphorylation of extracellular signal-regulated kinasein Raji cells but does not affect the growth of human CD34^+^ hematopoietic stem/progenitor cells, which can be significantly inhibited by compound **24** \[[@B53-molecules-22-00267]\].

Ten new acylated alkaloid derivatives were prepared from the natural diterpenoid alkaloids of *A. yesoense* var. *macroyesoense* and *A. japonicum*; they are 11,15-dianisoylpseudokobusine (**26**), 11,15-di-*p*-nitrobenzoylpseudokobusin (**27**), 11-(*p*-trifluoromethylbenzoyl)kobusine (**28**), 11-(*m*-trifluoromethylbenzoyl)kobusine (**29**), 11,15-di-*p*-nitrobenzoylkobusine (**30**), 11-*p*-nitrobenzoylpseudokobusine (**31**), 11-cinnamoylpseudokobusine (**32**), 6,11-dianisoylpseudokobusine (**33**), 11-veratroylpseudokobusine (**34**), and 11-anisoylpseudokobusine (**35**). They inhibited the growth of A549 cells through G1 arrest, and their IC~50~ values ranged within 1.72--5.44 µM. Their cytotoxic effects can be enhanced by replacing an acyl group at both C-11 and C-15 positions \[[@B54-molecules-22-00267]\].

In 2015, the antiproliferative effects of 108 diterpenoid alkaloids were tested by the same research team above against four cancer cells, namely, lung, prostate, nasopharyngeal, and vincristine-resistant nasopharyngeal (KB-VIN) cancer cell lines. The alkaloids that show substantial suppressive effects in 11 newly synthesized C~20~-diterpenoid alkaloid derivatives \[[@B55-molecules-22-00267]\]: 11,15-dibenzoylkobusine (**36**), 11,15-dianisoylkobusine (**37**), 11,15-di-(4-nitrobenzoyl)kobusine (**38**), 11,15-di-(4-fluorobenzoyl)kobusine (**39**), 11,15-di-(3-trifluoromethylcinnamoyl)kobusine (**40**), 11,15-dibenzoylpseudokobusine (**41**), 11-(4-nitrobenzoyl)pseudokobusine (**42**), 11,15-di-(3-nitrobenzoyl)pseudokobusine (**43**), 11-(3-trifluoromethylbenzoyl)pseudokobusine (**44**), 11-cinnamoylpseudokobusine (**45**), and 11-tritylpseudokobusine (**46**). All of them were hetisine-type C~20~-diterpenoid alkaloids with two different substitution patterns of C-11 and C-11, 15, and the GI~50~s of them were summarized in [Table 1](#molecules-22-00267-t001){ref-type="table"}.

3.4. Bis-Diterpenoid Alkaloids {#sec3dot4-molecules-22-00267}
------------------------------

Three bis-\[*O*-(14-benzoylaconine-8-yl)\]esters \[[@B56-molecules-22-00267]\], including new semisynthetic alkaloids with diverse alkyl chains on the heterocyclic moiety, including bis-\[*O*-(14-benzoylaconine-8-yl)\]-pimelate (**47**), bis-\[*O*-(14-benzoylaconine-8-yl)\]-suberate (**48**), and bis-\[*O*-(14-benzoylaconine-8-yl)\]-azelate (**49**), built from the 8-*O*-azeloyl-14-benzoylaconine (**11**) skeleton, present remarkable cytotoxic activity in vitro against lung cancer A-549, colon cancer HCT-15, and breast cancer MCF-7 cells; their IC~50~s were \<28 µM. The anticancer activities in vivo of bis-\[*O*-(14-benzoylaconine-8-yl)\]-suberate (**48**) was subsequently tested in immunodeficient mice transplanted with human tumors MCF-7 and HCT-15 cells because of its significant cytotoxicity in vitro. Its antitumor activity is obviously shown at a dose below the maximum tolerated dose. The impact of the alkyl-linker length of the designed bis-diterpenoid alkaloids on cytotoxicity is clearly elucidated in the study and can serve as a reference for designing novel antiproliferative agents \[[@B57-molecules-22-00267]\].

4. Discussion and Conclusions {#sec4-molecules-22-00267}
=============================

Diterpenoid alkaloids isolated and designed from *Aconitum* plants have shown effective anticancer properties in various cancer cell lines. Such properties include inhibiting cell growth, inducing apoptosis, interfering with the cell cycle, and altering MDR. The in vitro anticancer activities (IC~50~ values) of diterpenoid alkaloids derived from *Aconitum* and their derivatives are presented in [Table 1](#molecules-22-00267-t001){ref-type="table"}. Some of them also exert noteworthy anticancer effects in animal models.

Most of natural diterpenoid alkaloids with anticancer effect in *Aconitum* are C~19~-diterpenoid alkaloids, although derivatives of C~20~-diterpenoid alkaloids also have notable anticancer potential. Many diterpenoid alkaloids tend to exhibit improved activity after simple structural modification \[[@B58-molecules-22-00267]\], and many structures may affect the activity of a compound, such as the kind and position of substituents and the linker-chain length \[[@B59-molecules-22-00267]\].

Diterpenoid alkaloids from *Aconitum* have great potential use as new drugs for treating cancer. This review can serve as a useful reference for researchers in their search for highly effective, low-toxicity diterpenoid alkaloids through structure modification and structure--activity analysis. We also provide a theoretical basis for safety medication in clinical settings and further development of new anticancer drugs.
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molecules-22-00267-t001_Table 1

###### 

The anti-proliferative activities of the diterpenoid alkaloids derived from the genus *Aconitum.*

  No.                               Compounds                                                                                  Cancer Types                   Cell Lines   IC~50~                   Reference
  --------------------------------- ------------------------------------------------------------------------------------------ ------------------------------ ------------ ------------------------ -------------------------------
  **C~18~-diterpenoid alkaloids**                                                                                                                                                                   
  **1**                             Lappaconitine                                                                              Lung cancer                    A549         6.71 × 10^3^ µM/48 h     \[[@B39-molecules-22-00267]\]
  **C~19~-diterpenoid alkaloids**                                                                                                                                                                   
  **2**                             Lycaconitine                                                                               Fibroblast carcinoma           KB V20C      110.65 µM/72 h           \[[@B39-molecules-22-00267]\]
  **3**                             *Aconitine*                                                                                Oral squamous cell carcinoma   KBv200       348.29 µM/72 h           \[[@B42-molecules-22-00267]\]
                                                                                                                               Hepatoma carcinoma             Hepal-6      590.03 µM/48 h           \[[@B41-molecules-22-00267]\]
                                                                                                                               Hepatoma carcinoma             HePG2        0.85 × 10^−2^ µM/72 h    \[[@B47-molecules-22-00267]\]
                                                                                                                               Colon cancer                   HCT8         8.12 × 10^−2^ µM/72 h    
                                                                                                                               Breast cancer                  MCF7         2.45 × 10^−2^ µM/72 h    
  **4**                             (1α,6α,8α,14α,16α)-20-ethyl-8,14-dihydroxy-1,6,16-trimethoxy-4-(methoxymethyl)-aconitane   Leukemia                       HL-60        0.44 µM/24 h             \[[@B46-molecules-22-00267]\]
                                                                                                                               Leukemia                       K-562        1.55 µM/24 h             
  **5**                             Oxonitine                                                                                  Colon cancer                   HCT8         29.48 × 10^−2^ µM/72 h   \[[@B47-molecules-22-00267]\]
                                                                                                                               Breast cancer                  MCF7         3.13 × 10^−2^ µM/72 h    
                                                                                                                               Hepatoma carcinoma             HePG2        8.61 × 10^−2^ µM/72 h    
  **6**                             Deoxyaconitine                                                                             Colon cancer                   HCT8         5.14 × 10^−2^ µM/72 h    \[[@B47-molecules-22-00267]\]
                                                                                                                               Breast cancer                  MCF7         10.35 × 10^−2^µM/72 h    
                                                                                                                               Hepatoma carcinoma             HePG2        9.21 × 10^−2^ µM/72 h    
  **7**                             Hypaconitine                                                                               Colon cancer                   HCT8         12.05 × 10^−2^ µM/72 h   \[[@B47-molecules-22-00267]\]
                                                                                                                               Breast cancer                  MCF7         6.46 × 10^−2^ µM/72 h    
                                                                                                                               Hepatoma carcinoma             HePG2        0.92 × 10^−2^ µM/72 h    
  **8**                             Mesaconitine                                                                               Colon cancer                   HCT8         13.16 × 10^−2^ µM/72 h   \[[@B47-molecules-22-00267]\]
                                                                                                                               Breast cancer                  MCF7         4.57 × 10^−2^ µM/72 h    
                                                                                                                               Hepatoma carcinoma             HePG2        1.45 × 10^−2^ µM/72 h    
  **9**                             Crassicauline A                                                                            Colon cancer                   HCT8         16.45 × 10^−2^ µM/72 h   \[[@B47-molecules-22-00267]\]
                                                                                                                               Breast cancer                  MCF7         12.86 × 10^−2^ µM/72 h   
                                                                                                                               Hepatoma carcinoma             HePG2        2.36 × 10^−2^ µM/72 h    
  **10**                            8-*O*-Azeloyl-14-benzoylaconine                                                            Colon cancer                   HCT-15       16.8 µM/24h              \[[@B48-molecules-22-00267]\]
                                                                                                                               Lung cancer                    A549         19.4 µM/24 h             
                                                                                                                               Breast cancer                  MCF-7        10.3 µM/24 h             
  **11**                            Cammaconine                                                                                Gastric carcinoma              AGS          0.32 µM/48 h             \[[@B49-molecules-22-00267]\]
                                                                                                                               Hepatoma carcinoma             HepG2        34.55 µM/48 h            
                                                                                                                               Lung cancer                    A549         0.32 µM/48 h             
  **12**                            Neoline                                                                                    Gastric carcinoma              SGC-7901     37.55 µM/48 h            \[[@B50-molecules-22-00267]\]
                                                                                                                               Hepatoma carcinoma             HepG2        28.36 µM/48 h            
                                                                                                                               Lung cancer                    A549         34.74 µM/48 h            
  **13**                            14-*O*-acetylneoline                                                                       Gastric carcinoma              SGC-7901     16.97 µM/48 h            \[[@B50-molecules-22-00267]\]
                                                                                                                               Hepatoma carcinoma             HepG2        33.76 µM/48 h            
                                                                                                                               Lung cancer                    A549         18.75 µM/48 h            
  **C~20~-diterpenoid alkaloids**                                                                                                                                                                   
  **14**                            Atisinium chloride                                                                         Gastric carcinoma              AGS          0.44 µM/48 h             \[[@B49-molecules-22-00267]\]
                                                                                                                               Hepatoma carcinoma             HepG2        66.69 µM/48 h            
                                                                                                                               Lung cancer                    A549         2.29 µM/48 h             
  **15**                            Songorine                                                                                  Gastric carcinoma              SGC-7901     46.55 µM/48 h            \[[@B50-molecules-22-00267]\]
                                                                                                                               Hepatoma carcinoma             HepG2        87.72 µM/48 h            
                                                                                                                               Lung cancer                    A549         61.90 µM/48 h            
  **16**                            12-epi-napelline                                                                           Gastric carcinoma              SGC-7901     64.79 µM/48 h            \[[@B50-molecules-22-00267]\]
                                                                                                                               Hepatoma carcinoma             HepG2        96.99 µM/48 h            
                                                                                                                               Lung cancer                    A549         65.91 µM/48 h            
  **17**                            12-epi-dehydronapelline                                                                    Gastric carcinoma              SGC-7901     65.00 µM/48 h            \[[@B50-molecules-22-00267]\]
                                                                                                                               Hepatoma carcinoma             HepG2        46.63 µM/48 h            
                                                                                                                               Lung cancer                    A549         76.50 µM/48 h            
  **18**                            12-acetylluciculine                                                                        Malignant glioma               A172         13.95 µM/24 h            \[[@B51-molecules-22-00267]\]
  **19**                            Pseudokobusine                                                                             Malignant glioma               A172         \>15.18 µM/24 h          \[[@B51-molecules-22-00267]\]
  **20**                            6,11-dibenzoylpseudokobusine                                                               Malignant glioma               A172         2.42 µM/24 h             \[[@B51-molecules-22-00267]\]
  **21**                            11-veratroylpseudokobusine                                                                 Malignant glioma               A172         2.52 µM/24 h             \[[@B51-molecules-22-00267]\]
                                                                                                                               Lung cancer                    A549         3.5 µM/24 h              \[[@B52-molecules-22-00267]\]
  **22**                            11-cinnamoylpseudokobusine                                                                 Malignant glioma               A172         1.94 µM/24 h             \[[@B51-molecules-22-00267]\]
                                                                                                                               Lung cancer                    A549         5.1 µM/24 h              \[[@B52-molecules-22-00267]\]
  **23**                            11-(*m*-trifluoromethylbenzoyl)pseudokobusine                                              Malignant glioma               A172         Not shown                \[[@B51-molecules-22-00267]\]
                                                                                                                               Lung cancer                    A549         4.4 µM/24 h              \[[@B52-molecules-22-00267]\]
                                                                                                                               Lung cancer                    A549         4.67 µM/24 h             \[[@B54-molecules-22-00267]\]
                                                                                                                               Lymphoma                       Raji         4.39 µM/96 h             \[[@B53-molecules-22-00267]\]
  **24**                            11-anisoylpseudokobusine                                                                   Malignant glioma               A172         2.80 µM/24 h             \[[@B51-molecules-22-00267]\]
                                                                                                                               Lung cancer                    A549         1.7 µM/24 h              \[[@B52-molecules-22-00267]\]
                                                                                                                               Lymphoma                       Raji         5.18 µM/96 h             \[[@B53-molecules-22-00267]\]
  **25**                            11-*p*-nitrobenzoylpseudokobusine                                                          Malignant glioma               A172         3.13 µM/24 h             \[[@B51-molecules-22-00267]\]
                                                                                                                               Lung cancer                    A549         3.5 µM/24 h              \[[@B52-molecules-22-00267]\]
  **26**                            11,15-dianisoylpseudokobusine                                                              Lung cancer                    A549         1.72 µM/24 h             \[[@B54-molecules-22-00267]\]
  **27**                            11,15-di-*p*-nitrobenzoylpseudokobusin                                                     Lung cancer                    A549         2.66 µM/24 h             \[[@B54-molecules-22-00267]\]
  **28**                            11-(*p*-trifluoromethylbenzoyl)kobusine                                                    Lung cancer                    A549         5.44 µM/24 h             \[[@B54-molecules-22-00267]\]
  **29**                            11-(*m*-trifluoromethylbenzoyl)kobusine                                                    Lung cancer                    A549         3.75 µM/24 h             \[[@B54-molecules-22-00267]\]
  **30**                            11,15-di-*p*-nitrobenzoylkobusine                                                          Lung cancer                    A549         5.08 µM/24 h             \[[@B54-molecules-22-00267]\]
  **31**                            11-*p*-nitrobenzoylpseudokobusine                                                          Lung cancer                    A549         4.24 µM/24 h             \[[@B54-molecules-22-00267]\]
  **32**                            11-cinnamoylpseudokobusine                                                                 Lung cancer                    A549         3.02 µM/24 h             \[[@B54-molecules-22-00267]\]
  **33**                            6,11-dianisoylpseudokobusine                                                               Lung cancer                    A549         3.68 µM/24 h             \[[@B54-molecules-22-00267]\]
  **34**                            11-veratroylpseudokobusine                                                                 Lung cancer                    A549         4.07 µM/24 h             \[[@B54-molecules-22-00267]\]
  **35**                            11-anisoylpseudokobusine                                                                   Lung cancer                    A549         2.20 µM/24 h             \[[@B54-molecules-22-00267]\]
  **36**                            11,15-dibenzoylkobusine                                                                    Lung cancer                    A549         GI~50~ = 8.4 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 9.3 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 6.0 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 7.5 µM/72 h     
  **37**                            11,15-dianisoylkobusine                                                                    Lung cancer                    A549         GI~50~ = 6.7 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 7.1 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 5.3 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 5.2 µM/72 h     
  **38**                            11,15-di-(4-nitrobenzoyl)kobusine                                                          Lung cancer                    A549         GI~50~ = 6.9 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 7.0 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 5.3 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 5.5 µM/72 h     
  **39**                            11,15-di-(4-fluorobenzoyl)kobusine                                                         Lung cancer                    A549         GI~50~ = 8.1 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 6.8 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 5.2 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 7.1 µM/72 h     
  **40**                            11,15-di-(3-trifluoromethylcinnamoyl)kobusine                                              Lung cancer                    A549         GI~50~ = 5.5 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 6.2 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 4.1 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 3.1 µM/72 h     
  **41**                            11,15-dibenzoylpseudokobusine                                                              Lung cancer                    A549         GI~50~ = 8.8 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 7.6 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 5.2 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 6.3 µM/72 h     
  **42**                            11-(4-nitrobenzoyl)pseudokobusine                                                          Lung cancer                    A549         GI~50~ = 5.8 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 7.2 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 6.4 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 6.4 µM/72 h     
  **43**                            11,15-di-(3-nitrobenzoyl)pseudokobusine                                                    Lung cancer                    A549         GI~50~ = 5.0 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 5.2 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 5.6 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 5.6 µM/72 h     
  **44**                            11-(3-trifluoromethylbenzoyl)pseudokobusine                                                Lung cancer                    A549         GI~50~ = 6.8 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 7.7 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 8.9 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 6.2 µM/72 h     
  **45**                            11-cinnamoylpseudokobusine                                                                 Lung cancer                    A549         GI~50~ = 8.4 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 6.5 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 7.0 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 6.4 µM/72 h     
  **46**                            11-tritylpseudokobusine                                                                    Lung cancer                    A549         GI~50~ = 6.4 µM/72 h     \[[@B55-molecules-22-00267]\]
                                                                                                                               Prostate cancer                DU145        GI~50~ = 6.0 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB           GI~50~ = 6.6 µM/72 h     
                                                                                                                               Epidermoid carcinoma           KB-VIN       GI~50~ = 5.3 µM/72 h     
  **Bis-diterpenoid alkaloids**                                                                                                                                                                     
  **47**                            Bis-\[*O*-(14-benzoylaconine-8-yl)\]-pimelate                                              Lung cancer                    A549         9.50 µM/72 h             \[[@B56-molecules-22-00267]\]
                                                                                                                               Breast cancer                  MCF-7        7.56 µM/72 h             
                                                                                                                               Colon cancer                   HCT-15       4.64 µM/72 h             
  **48**                            Bis-\[*O*-(14-benzoylaconine-8-yl)\]-suberate                                              Lung cancer                    A549         7.53 µM/72 h             \[[@B56-molecules-22-00267]\]
                                                                                                                               Breast cancer                  MCF-7        6.90 µM/72 h             
                                                                                                                               Colon cancer                   HCT-15       4.01 µM/72 h             
  **49**                            Bis-\[*O*-(14-benzoylaconine-8-yl)\]-azelate                                               Lung cancer                    A549         19.5 µM/72 h             \[[@B56-molecules-22-00267]\]
                                                                                                                               Breast cancer                  MCF-7        16.9 µM/72 h             
                                                                                                                               Colon cancer                   HCT-15       28.0 µM/72 h             
